High materiality7/10
Vyome initiated with a Buy at Chardan
Why it may matterVerify against the original reporting
buy
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Vyome Therapeutics initiated with Buy at Chardan; target $3.50; current price $2.18.
- Vyome initiated with Buy at Chardan; tgt $3.50.
- Upside potential >60%.
Key facts
- 01
Target: $3.5
- 02
Posted price: $2.18
- 03
Analyst firm: Chardan Capital
- 04
Analyst: Keay Nakae
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.